Dendritic Cell p53 Vaccine
p53 is an attractive target for cancer immunotherapy. Dendritic cells transduced with wild-type p53 gene can elicit potent anti-tumor immune responses. As a leading service provider in the field of vaccine for years, Creative Biolabs can provide customers with professional co-development services for cancer immunotherapy in a customer leading manner.
p53 Gene
p53 is a nucleoprotein, and peptide fragments of this protein may be presented on the cell surface-associated with MHC class I or class II. p53 is an attractive target for the immunotherapy of cancer as many types of cancer have been found to be associated with mutations in the p53 gene, which often result in significant over-expression of the protein in tumour cells. Significant overexpression of p53 may often observed in tumour cells even without mutation in the gene. These multiple epitopes which are generated by p53 over-expression can be used as excellent targets for cancer immunotherapy. It has been demonstrated the generation of anti-tumour immune responses using mutant p53 peptides as antigens. A number of peptides derived from wild-type p53 that bind to the HLA A2 molecule have been successfully used to stimulate anti-p53 specific CTL responses in control donor and cancer patients. Adoptive transfer of wild-type p53-specific CTL results in eradication of p53+ tumors without disrupting normal tissues in animal models. These data indicate that immune and anti-tumor responses to "self" epitopes in wild-type p53 protein can be induced without clinically significant autoimmunity.
Fig.1 Mutant p53 promotes adaptive responses to cancer-related stress conditions to support tumor progression. Cancer cells in a growing tumor are exposed to multiple intrinsic and extrinsic stress conditions. (Mantovani F. 2019)
Human Wild-type p53 Containing Recombinant Adenovirus (Ad-p53)
Regardless of the mitotic state of the cells, adenoviruses can provide high levels of transduction efficacy for a variety of cell types. In some human clinical trials without major adverse events, the replication-deficient adenovirus deleted in the E1 region has been injected directly into the human body. Ad-p53 DC vaccine is comprised of the cancer patient’s dendritic cells infected in the laboratory with a genetically engineered adenovirus carrying the human p53 gene (Ad-p53). This vaccine is designed to activate the immune system to attack tumor cells which express high levels of p53 in many types of cancer.
Ad-p53 DC Vaccine
The Ad-p53 DC vaccine is made using dendritic cells transduced with human wild-type p53 containing recombinant adenovirus (Ad-p53). Treatment with Ad-p53-transduced DC can induce specific immune responses against tumor cells expressing different mutant p53 genes, including p53 genes of different species, and this immune response is sufficient to protect the tumor and can significantly slow the growth of established tumors. Therefore, DC transduced with wild-type p53 may be a promising new tool for cancer immunotherapy.
Creative Biolabs is a preclinical-stage CRO dedicated to the research and development of drugs for the treatment of cancer. If you are interested in our services, please contact us to get more information or directly send us an online inquiry.
Reference
- Mantovani F, et al. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019, 26(2):199-212.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
